高流量内分泌外科医生主导的成本削减举措在大卫生系统中的效果
结果显示干预后手术室成本降低27.5%,总直接成本降低17%,而对照组成本上升9%。
要点
- 干预后手术室成本降低27.5%(0.631-0.458,P < .001)。
- 总直接成本降低17%(P < .001),所有术式降幅-15%至-22%。
- 未干预对照组同期总成本上升9%(P < .001)。
核心结论
- 针对外科医生个体化的成本反馈与教育可产生持续的成本降低,而非干预组成本随时间上升。
研究设计与样本
- 共分析3,622例甲状腺和甲状旁腺手术的财务数据。
主要发现
- 基线时内分泌外科医生直接成本分别比高流量和低流量医生低14%和26%。
- 干预后手术室成本降低27.5%(0.631-0.458,P < .001),总直接成本降低17%(P < .001)。
- 成本降低见于所有术式(-15%至-22%,P < .001),成本变异性下降(P < .001)。
- 两个对照组同期总成本上升9%(P < .001)。
临床怎么用
- 可将个体化成本反馈、耗材使用教育及供应商合作作为可推广的成本控制模式用于其他外科服务线。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hospital economics are challenged by increased costs with limited growth in reimbursement. While individual surgeons have little impact on these factors, they can control instrumentation and disposables used in the operating room. We implemented a cost reduction initiative among high-volume endocrine surgeons and compared its financial impact with other cohorts performing equivalent procedures. METHODS: A cost optimization program was introduced in December 2024 among surgeons from the Endocrine Surgery Department, combining individualized cost feedback and education on the use of supplies and instruments and vendor collaboration to identify lower-cost alternatives. Financial data preintervention and postintervention (January 2024-December 2025) were analyzed. Outcomes were benchmarked against high-volume (>50 cases/y) and low-volume surgeons who did not undergo the intervention. Five procedural categories were evaluated: all cases combined, parathyroidectomy, thyroid lobectomy, total thyroidectomy, and complex cases. RESULTS: Financial data were analyzed for 3,622 thyroid and parathyroid procedures. At baseline, endocrine surgeons demonstrated 14% and 26% lower direct costs compared with high- and low-volume surgeons, respectively. Following implementation, a 27.5% reduction in operating room costs was achieved (0.631-0.458; P < .001), which translated into a 17% overall direct cost reduction (P < .001). This was observed across all procedure types (-15% to -22%; P < .001). Cost variability decreased (P < .001). Both control groups demonstrated an overall increase of 9% over the same period (P < .001). CONCLUSION: While costs rose over time in nonintervention groups, targeted surgeon-driven interventions produced sustained cost reductions, offering a scalable model for other service lines seeking to maintain profitability under constrained payment models.
引用
- Canalizo, Bauzon, Thelen, et al. Impact of a cost reduction initiative among high-volume endocrine surgeons in a large health system. Surgery. 2026. PMID: 42951757. doi:10.1016/j.surg.2026.110657
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。